Chris Dimitropoulos
Angel Investor · at Alpha Wave Ventures
New York, United States
Chris Dimitropoulos is a Series B investor at Alpha Wave Ventures in New York focused on Medical and Biotechnology. Managing Director
- Total investments:
- 11
- Last investment:
- Lead investor:
- 73%
Last updated:
For AI agents: llms.txt
Industries Chris Dimitropoulos invests in
Stages Chris Dimitropoulos invests in
Countries Chris Dimitropoulos invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 4 (36%)
- Biotechnology 4 (36%)
- Biopharma 3 (27%)
- Health Care 3 (27%)
- Life Science 2 (18%)
Stage
- Series B 5 (45%)
- Series C 2 (18%)
- Series A 1 (9%)
- Series D 1 (9%)
- Venture - Series Unknown 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Moonwalk Biosciences is a genomic medicine startup that aims to provide a new class of precision epigenetic therapeutics. The company is working on the development of a profiling and engineering technology platform that, with the help of advanced artificial intelligence prediction, provides a comprehensive view of the epigenome in health anddisease, allowing healthcare providers to take a fresh look at how therapies are discovered and developed. | $70M / Series B / Sep 08, 2026 | ||
| Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $50M / Series B / Jun 18, 2026 | ||
| HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $102M / Series D / Aug 15, 2024 | ||
| Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology inall systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options. | $56M / Series B / Feb 06, 2024 | ||
| Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $105M / Series A / Jan 30, 2024 | ||
| Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases. The company's lead product, felzartamab, is a fully human anti-CD38 monoclonal antibody that has been shown in clinical studies to deplete CD38+ cells that include plasma cells and natural killer, or NK, cells which mayallow for applications that improve clinical outcomes in a broad range of immune-mediated diseases. | $95M / Series B / Jan 04, 2024 | ||
| Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. | $45M / Series C / Nov 21, 2023 | ||
| Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. | $25M / Series B / Jan 30, 2023 | ||
| Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.Sleep apnea is a common, serious condition with significant morbidity, increased mortality, and substantial effects on daily functioning. Sleep apnea affects more than 20 million Americans and has seriousconsequences. OSA is caused by a combination of predisposing anatomical factors and sleep-related decrements of activity in upper airway muscles.Current treatments primarily rely on positive pressure devices, e.g., CPAP, to maintain airway patency. Less commonly used treatments include mandibular advancement devices, nerve stimulation, and surgical interventions.Apnimed, Inc. was founded in 2017 and is located in Cambridge, Massachusetts. | $79.7M / Series C / Dec 23, 2022 | ||
| Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $30M / Venture - Series Unknown / Sep 07, 2022 | ||
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Chris Dimitropoulos invest in?
Chris Dimitropoulos invests primarily in Medical, Biotechnology and Biopharma startups, most often at Series B and Series C stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Chris Dimitropoulos?
Public channels for Chris Dimitropoulos include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Chris Dimitropoulos last invest?
The most recent investment recorded for Chris Dimitropoulos closed in Sep 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
